Health

Ema, CHMP approves four new drugs (two orphans) in April

ADVERTISING
Rome, 26 April – At its last meeting between 19 and 22 April, the EMA Committee for Medicinal Products for Human Use (CHMP) recommended the approval of four new medicines, the extension of therapeutic indications for seven medicines and some post-examination measures. some other medicines.
The new drugs proposed for approval are Filsuvez, orphan drug based on birch bark extract for the treatment of bullosa epidermolysis. Lunsumio (mosunetuzumab), also an orphan medicine, for the treatment of recurrent or persistent follicular lymphoma (conditional marketing authorization is recommended). Tabrecta (capatinib). for the treatment of advanced non-small cell lung cancer and finally the generic drug Pirfenidone AET (pirfenidone) for the treatment of idiopathic pulmonary fibrosis.

ADVERTISING

ADVERTISING
1 of 6